Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
Phase NA Terminated
1 enrolled 3 charts
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Phase 2 Terminated
41 enrolled 13 charts
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Terminated
150 enrolled
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Phase 2 Terminated
1 enrolled 4 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
Phase 1 Terminated
26 enrolled
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Terminated
1,000 enrolled
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Phase 2 Terminated
16 enrolled 19 charts
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
Phase 2 Terminated
24 enrolled 15 charts
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Terminated
16 enrolled 7 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Phase NA Terminated
43 enrolled
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
Phase 1 Terminated
4 enrolled
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase 1 Terminated
3 enrolled
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase NA Terminated
1 enrolled 7 charts
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Phase 2 Terminated
1 enrolled 5 charts
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Terminated
1 enrolled 5 charts
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
Phase 3 Terminated
240 enrolled
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
Terminated
9 enrolled
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Phase 2 Terminated
6 enrolled 5 charts
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Phase NA Terminated
30 enrolled
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
Phase NA Terminated
16 enrolled 6 charts
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
Phase 1 Terminated
6 enrolled
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
Phase NA Terminated
9 enrolled
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
Terminated
24 enrolled
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
Terminated
48 enrolled
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
Phase 2 Terminated
14 enrolled 5 charts
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
Phase NA Terminated
6 enrolled 13 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase 1 Terminated
36 enrolled
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Phase 1 Terminated
4 enrolled
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Terminated
252 enrolled
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
Phase 2 Terminated
51 enrolled
Studying Fentanyl in Patients With Cancer
Terminated
2 enrolled
MPDMDSBMT
Phase 2 Terminated
7 enrolled
Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
Phase NA Terminated
351 enrolled
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
Phase NA Terminated
4 enrolled
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Phase 2 Terminated
5 enrolled 5 charts
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
Terminated
60 enrolled
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Phase 1 Terminated